PT - JOURNAL ARTICLE AU - Laura H. Heitman AU - Julia Oosterom AU - Kimberly M. Bonger AU - Cornelis M. Timmers AU - Peter H. G. Wiegerinck AU - Adriaan P. IJzerman TI - [<sup>3</sup>H]Org 43553, the First Low-Molecular-Weight Agonistic and Allosteric Radioligand for the Human Luteinizing Hormone Receptor AID - 10.1124/mol.107.039875 DP - 2008 Feb 01 TA - Molecular Pharmacology PG - 518--524 VI - 73 IP - 2 4099 - http://molpharm.aspetjournals.org/content/73/2/518.short 4100 - http://molpharm.aspetjournals.org/content/73/2/518.full SO - Mol Pharmacol2008 Feb 01; 73 AB - The luteinizing hormone (LH) receptor plays a pivotal role in reproduction. The high-molecular-weight (HMW) human chorionic gonadotropin (hCG) and LH are the endogenous ligands of this receptor and bind to its large N terminus. The present study characterizes the binding of a new low-molecular-weight (LMW) radioligand, [3H]5-amino-2-methylsulfanyl-4-[3-(2-morpholin-4-yl-acetylamino)-phenyl]-thieno[2,3-d]pyrimidine-6-carboxylic acid tert-butylamide (Org 43553), at the LH receptor. Equilibrium saturation and displacement assays were developed and optimized. Specific binding of [3H]Org 43553 to CHO-K1 cell membranes expressing the human LH receptor and a cAMP response element-luciferase reporter gene was saturable with a KD value of 2.4 ± 0.4 nM and a Bmax value of 1.6 ± 0.2 pmol/mg protein. Affinities of five LMW analogs of Org 43553 were determined. All displaced the radioligand competitively, with Ki values ranging from 3.3 to 100 nM. Finally, the potency of these compounds in a cAMP-induced luciferase assay was also determined. There was a high correlation between affinity and potency (r = 0.99; P &lt; 0.0001) of these compounds. In the search for LMW ligands, which bind allosterically to the seven-transmembrane domain of the LH receptor, a HMW radioligand (e.g., 125I-hCG) is not suitable as it is not displaced by a LMW compound. Therefore, [3H]Org 43553, a new radioligand with good binding properties, allows screening for new LMW ligands that mimic the action of the endogenous hormone at the LH receptor. The American Society for Pharmacology and Experimental Therapeutics